Oncimmune Holdings PLC Investor Presentation via Investor Meet Company

RNS Number : 9148O

Oncimmune Holdings PLC

17 May 2024

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Investor Presentation via Investor Meet Company

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, is pleased to announce that Martin Gouldstone, CEO, and Martin Hudson, Finance Director, will provide a live presentation relating to the unaudited interim results for the six months ended 29 February 2024 ("H1 FY2024"), which are expected to be announced on Tuesday 21 May, via Investor Meet Company on 21 May 2024, 14:00 BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 20 May 2024, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Oncimmune via:

 

https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

 

Investors who already follow Oncimmune on the Investor Meet Company platform will automatically be invited.

               

For further information please contact:

 

Oncimmune Holdings plc
[e-mail]
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, George Dollemore, Trisyia Jamaludin (Corporate Finance)   Nigel Birks, Ondraya Swanson (ECM) [phone]
Zeus Capital Limited (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate [phone] [phone]

 

Notes to Editors

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

 

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

 

 

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCGCGDUCGBDGSR